Regen BioPharma, Inc.
RGBP
$0.055
$0.0011.85%
OTC PK
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 0.51% | 0.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.51% | 0.00% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 0.51% | 0.00% | |||
| SG&A Expenses | -16.58% | 12.08% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.75% | 4.31% | |||
| Operating Income | 20.00% | -6.82% | |||
| Income Before Tax | -103.61% | -6.20% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -103.61% | -6.20% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -103.61% | -6.20% | |||
| EBIT | 20.00% | -6.82% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -110.79% | 10.32% | |||
| Normalized Basic EPS | -88.66% | 0.00% | |||
| EPS Diluted | -110.79% | 10.32% | |||
| Normalized Diluted EPS | -88.66% | 0.00% | |||
| Average Basic Shares Outstanding | 7.22% | 6.92% | |||
| Average Diluted Shares Outstanding | 7.22% | 6.92% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||